Optimized clinical application of minimal residual disease in acute myeloid leukemia with RUNX1 –RUNX1T1

Acute myeloid leukemia (AML) with t(8;21)/RUNX1 –RUNX1T1 is a heterogeneous disease with different prognoses although it is stratified in the favorable risk group according to guidelines [1–3]. Minimal (measurable) residual disease (MRD) detection and monitoring are increasingly applied in clinical practice and are becoming a factor in decisi on-making for some therapeutic stratifications. MRD monitoring by quantitative reverse transcription polymerase chain reaction (qRT-PCR) is feasible, and the results are significantly associated with outcomes in AML with RUNX1–RUNX1T1 [4].

Source: Experimental Hematology - January 29, 2021 Category: Hematology Authors: Hui Wei, Xueou Liu, Ying Wang, Dong Lin, Chunlin Zhou, Bingcheng Liu, Shaowei Qiu, Runxia Gu, Yan Li, Shuning Wei, Benfa Gong, Kaiqi Liu, Xiaoyuan Gong, Yuntao Liu, Guangji Zhang, Qiuyun Fang, Junping Zhang, Jingjing Jin, Yueshen Ma, Yingchang Mi, Jianxia Source Type: research